Is Macrophage Migration Inhibitory Factor a Link between Inflammation and Tumor?
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Published
Jan 31, 2023
Abstract
Macrophage migration inhibitory factor (MIF) is a classic pro-inflammatory factor that helps control both innate and adaptive immune responses. The expression of MIF is much higher in many tumor tissues, which helps the tumor grow, spread, make new blood vessels, and create an immune microenvironment that helps the tumor. Due to the important role MIF plays in the development and growth of tumors, it is being looked at as a possible way to treat tumors. This review discusses what MIF is, where it is found, how it sends signals, what it does in inflammation and tumors, and how drugs that target MIF are being made.
##plugins.themes.bootstrap3.article.details##
Keywords
Macrophage Migration Inhibitory Factor, Inflammation, Tumor, Microenvironment, Therapeutic Target
References
1. Virchov R. Cellular pathology as based upon physiological and pathological histology. Philadelphia: J. B. Lippincott; 1863.
2. Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858. Nutr Rev 1989; 47(1):23-25. DOI: https://doi.org/10.1111/j.1753-4887.1989.tb02747.x
3. Francescone R, Hou V, Grivennikov SI. Microbiome, inflammation, and cancer. Cancer J 2014; 20(3):181-189. DOI: https://doi.org/10.1097/PPO.0000000000000048
4. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2017; 9(6):7204-7218. DOI: https://doi.org/10.18632/oncotarget.23208
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140(6):883-899. DOI: https://doi.org/10.1016/j.cell.2010.01.025
6. Fan Y, Mao R, Yang J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 2013; 4(3):176-185. DOI: https://doi.org/10.1007/s13238-013-2084-3
7. Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res 2014; 2(9):823-830. DOI: https://doi.org/10.1158/2326-6066.CIR-14-0112
8. Kasama T, Ohtsuka K, Sato M, Takahashi R, Wakabayashi K, Kobayashi K. Macrophage migration inhibitory factor: A multifunctional cytokine in rheumatic diseases. Arthritis 2010; 2010:106202. DOI: https://doi.org/10.1155/2010/106202
9. Sugimoto H, Taniguchi M, Nakagawa A, Tanaka I, Suzuki M, Nishihira J. Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 A resolution. Biochemistry 1999; 38(11):3268-3279. DOI: https://doi.org/10.1021/bi982184o
10. Grieb G, Merk M, Bernhagen J, Bucala R. Macrophage migration inhibitory factor (MIF): A promising biomarker. Drug News Perspect 2010; 23(4):257-264. DOI: https://doi.org/10.1358/dnp.2010.23.4.1453629
11. Schinagl A, Thiele M, Douillard P, Völkel D, Kenner L, Kazemi Z, Freissmuth M, Scheiflinger F, Kerschbaumer RJ. Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer. Oncotarget 2016; 7(45):73486-73496. DOI: https://doi.org/10.18632/oncotarget.11970
12. Guda MR, Rashid MA, Asuthkar S, Jalasutram A, Caniglia JL, Tsung AJ, Velpula KK. Pleiotropic role of macrophage migration inhibitory factor in cancer. Am J Cancer Res 2019; 9(12):2760-2773
13. Bloom J, Metz C, Nalawade S, Casabar J, Cheng KF, He M, Sherry B, Coleman T, Forsthuber T, Al-Abed Y. Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. J Biol Chem 2016; 291(51):26502-26514. DOI: https://doi.org/10.1074/jbc.M116.743328
14. Skeens E, Pantouris G, Shah D, Manjula R, Ombrello MJ, Maluf NK, Bhandari V, Lisi GP, Lolis EJ. A cysteine variant at an allosteric site alters MIF dynamics and biological function in homo- and heterotrimeric assemblies. Front Mol Biosci 2022; 9:783669. DOI: https://doi.org/10.3389/fmolb.2022.783669
15. Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol 2005; 18(1):41-78. DOI: https://doi.org/10.1089/vim.2005.18.41
16. Trivedi-Parmar V, Jorgensen WL. Advances and insights for small molecule inhibition of macrophage migration inhibitory factor. J Med Chem 2018; 61(18):8104-8119. DOI: https://doi.org/10.1021/acs.jmedchem.8b00589
17. Stamps SL, Fitzgerald MC, Whitman CP. Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor. Biochemistry 1998; 37(28):10195-10202. DOI: https://doi.org/10.1021/bi9806955
18. Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, Jüttner S, Brunner H, Bernhagen J. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 1998; 280(1):85-102. DOI: https://doi.org/10.1006/jmbi.1998.1864
19. Nguyen MT, Lue H, Kleemann R, Thiele M, Tolle G, Finkelmeier D, Wagner E, Braun A, Bernhagen J. The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis. J Immunol 2003; 170(6):3337-3347. DOI: https://doi.org/10.4049/jimmunol.170.6.3337
20. Fingerle-Rowson G, Koch P, Bikoff R, Lin X, Metz CN, Dhabhar FS, Meinhardt A, Bucala R. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 2003; 162(1):47-56. DOI: https://doi.org/10.1016/S0002-9440(10)63797-2
21. Calandra T, Roger T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 2003; 3(10):791-800. DOI: https://doi.org/10.1038/nri1200
22. Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R. Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1995; 1(7):781-8
23. Martinez-Guzman MA, Alvarado-Navarro A, Delgado-Rizo V, Garcia-Orozco A, Mayorga-Rodríguez JA, Pereira-Suarez AL, Fafutis-Morris M. Serum levels of migration inhibitory factor (MIF) and in situ expression of MIF and its receptor CD74 in lepromatous leprosy patients: A preliminary report. Front Immunol 2018; 9:246. DOI: https://doi.org/10.3389/fimmu.2018.00246
24. Merk M, Baugh J, Zierow S, Leng L, Pal U, Lee SJ, Ebert AD, Mizue Y, Trent JO, Mitchell R, Nickel W, Kavathas PB, Bernhagen J, Bucala R. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol 2009; 182(11):6896-6906. DOI: https://doi.org/10.4049/jimmunol.0803710
25. Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett 2003; 551(1-3):78-86. DOI: https://doi.org/10.1016/s0014-5793(03)00900-1
26. Lee YR, Joo HK, Lee EO, Cho HS, Choi S, Kim CS, Jeon BH. ATP binding cassette transporter A1 is involved in extracellular secretion of acetylated APE1/Ref-1. Int J Mol Sci 2019; 20(13):3178. DOI: https://doi.org/10.3390/ijms20133178
27. Burger-Kentischer A, Finkelmeier D, Thiele M, Schmucker J, Geiger G, Tovar GE, Bernhagen J. Binding of JAB1/CSN5 to MIF is mediated by the MPN domain but is independent of the JAMM motif. FEBS Lett 2005; 579(7):1693-1701. DOI: https://doi.org/10.1016/j.febslet.2005.01.080
28. Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, Bernhagen J. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 2006; 18(5):688-703. DOI: https://doi.org/10.1016/j.cellsig.2005.06.013
29. Lee JP, Foote A, Fan H, Peral de Castro C, Lang T, Jones SA, Gavrilescu N, Mills KH, Leech M, Morand EF, Harris J. Loss of autophagy enhances MIF/macrophage migration inhibitory factor release by macrophages. Autophagy 2016; 12(6):907-916. DOI: https://doi.org/10.1080/15548627.2016.1164358
30. Wu J, Deng X, Gao J, Gao W, Xiao H, Wang X, Zhang Y. Autophagy mediates the secretion of macrophage migration inhibitory factor from cardiomyocytes upon serum-starvation. Sci China Life Sci 2019; 62(8):1038-1046. DOI: https://doi.org/10.1007/s11427-019-9567-1
31. Rajasekaran D, Gröning S, Schmitz C, Zierow S, Drucker N, Bakou M, Kohl K, Mertens A, Lue H, Weber C, Xiao A, Luker G, Kapurniotu A, Lolis E, Bernhagen J. Macrophage migration inhibitory factor-CXCR4 receptor interactions: Evidence for partial allosteric agonism in comparison with CXCL12 chemokine. J Biol Chem 2016; 291(30):15881-15895. DOI: https://doi.org/10.1074/jbc.M116.717751
32. Schwartz V, Lue H, Kraemer S, Korbiel J, Krohn R, Ohl K, Bucala R, Weber C, Bernhagen J. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett 2009; 583(17):2749-2757. DOI: https://doi.org/10.1016/j.febslet.2009.07.058
33. Alampour-Rajabi S, El Bounkari O, Rot A, Müller-Newen G, Bachelerie F, Gawaz M, Weber C, Schober A, Bernhagen J. MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis. FASEB J 2015; 29(11):4497-511. DOI: https://doi.org/10.1096/fj.15-273904
34. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197(11):1467-1476. DOI: https://doi.org/10.1084/jem.20030286
35. Subbannayya T, Variar P, Advani J, Nair B, Shankar S, Gowda H, Saussez S, Chatterjee A, Prasad TS. An integrated signal transduction network of macrophage migration inhibitory factor. J Cell Commun Signal 2016; 10(2):165-170. DOI: https://doi.org/10.1007/s12079-016-0326-x
36. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008; 283(5):2784-2792. DOI: https://doi.org/10.1074/jbc.M703265200
37. Fex Svenningsen Å, Löring S, Sørensen AL, Huynh HUB, Hjæresen S, Martin N, Moeller JB, Elkjær ML, Holmskov U, Illes Z, Andersson M, Nielsen SB, Benedikz E. Macrophage migration inhibitory factor (MIF) modulates trophic signaling through interaction with serine protease HTRA1. Cell Mol Life Sci 2017; 74(24):4561-4572. DOI: https://doi.org/10.1007/s00018-017-2592-z
38. Kim MJ, Kim WS, Kim DO, Byun JE, Huy H, Lee SY, Song HY, Park YJ, Kim TD, Yoon SR, Choi EJ, Ha H, Jung H, Choi I. Macrophage migration inhibitory factor interacts with thioredoxin-interacting protein and induces NF-κB activity. Cell Signal 2017; 34:110-120. DOI: https://doi.org/10.1016/j.cellsig.2017.03.007
39. Shen L, Hu J, Lu H, Wu M, Qin W, Wan D, Li YY, Gu J. The apoptosis-associated protein BNIPL interacts with two cell proliferation-related proteins, MIF and GFER. FEBS Lett 2003; 540(1-3):86-90. DOI: https://doi.org/10.1016/s0014-5793(03)00229-1
40. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000; 408(6809):211-216. DOI: https://doi.org/10.1038/35041591
41. Gandhi J, Khera L, Gaur N, Paul C, Kaul R. Role of modulator of inflammation cyclooxygenase-2 in gamma herpesvirus mediated tumorigenesis. Front Microbiol 2017; 8:538. DOI: https://doi.org/10.3389/fmicb.2017.00538
42. Wang F, Wu H, Xu S, Guo X, Yang J, Shen X. Macrophage migration inhibitory factor activates cyclooxygenase 2-prostaglandin E2 in cultured spinal microglia. Neurosci Res 2011; 71(3):210-218. DOI: https://doi.org/10.1016/j.neures.2011.07.1821
43. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010; 2010:215158. DOI: https://doi.org/10.1155/2010/215158
44. Ramon S, Woeller CF, Phipps RP. The influence of Cox-2 and bioactive lipids on hematological cancers. Curr Angiogenes 2013; 2(2):135-142. DOI: https://doi.org/10.2174/2211552802999140131105947
45. Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V, Lara-Riegos J, Ramírez-Camacho MA, Alvarez-Sánchez ME. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol 2019; 9:1370. DOI: https://doi.org/10.3389/fonc.2019.01370
46. Yu X, Lin SG, Huang XR, Bacher M, Leng L, Bucala R, Lan HY. Macrophage migration inhibitory factor induces MMP-9 expression in macrophages via the MEK-ERK MAP kinase pathway. J Interferon Cytokine Res 2007; 27(2):103-109. DOI: https://doi.org/10.1089/jir.2006.0054
47. Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 1999; 19(8):5800-5810. DOI: https://doi.org/10.1128/MCB.19.8.5800
48. Dai Y, Jin S, Li X, Wang D. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget 2017; 8(1):1354-1368. DOI: https://doi.org/10.18632/oncotarget.13817. Erratum in: Oncotarget 2020; 11(4):488-489.
49. Mangano K, Mazzon E, Basile MS, Di Marco R, Bramanti P, Mammana S, Petralia MC, Fagone P, Nicoletti F. Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. Oncotarget 2018; 9(25):17951-17970. DOI: https://doi.org/10.18632/oncotarget.24885
50. Guo X, Xu S, Gao X, Wang J, Xue H, Chen Z, Zhang J, Guo X, Qian M, Qiu W, Li G. Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via CXCR4/AKT/EMT pathway in human glioblastoma cells. Oncotarget 2017; 8(46):80358-80372. DOI: https://doi.org/10.18632/oncotarget.18673
51. Amin MA, Haas CS, Zhu K, Mansfield PJ, Kim MJ, Lackowski NP, Koch AE. Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood 2006; 107(6):2252-2261. DOI: https://doi.org/10.1182/blood-2005-05-2011
52. Jung H, Seong HA, Ha H. Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J Biol Chem 2008; 283(29):20383-20396. DOI: https://doi.org/10.1074/jbc.M800050200
53. David JR, Remold HG, Higgins TJ, Liu DY, Churchill WH, Wilkinson PC, & Blussé van Oud Alblas A. MIF/MAF-macrophage interactions: Biochemical characterization of a putative glycolipid receptor for MIF and the existence and properties of two distinct MIFs. In: van Furth, R. (eds) Mononuclear Phagocytes. Springer, Dordrecht. 1980. DOI: https://doi.org/10.1007/978-94-009-8793-7_20
54. Wang F, Gao F, Jing L. Is macrophage migration inhibitory factor (MIF) the "control point" of vascular hypo-responsiveness in septic shock? Med Hypotheses 2005; 65(6):1082-1087. DOI: https://doi.org/10.1016/j.mehy.2005.05.047
55. Lan HY, Yang N, Metz C, Mu W, Song Q, Nikolic-Paterson DJ, Bacher M, Bucala R, Atkins RC. TNF-alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol Med 1997; 3(2):136-44.
56. Nishihira J. Molecular function of macrophage migration inhibitory factor and a novel therapy for inflammatory bowel disease. Ann N Y Acad Sci 2012; 1271(1):53-57. DOI: https://doi.org/10.1111/j.1749-6632.2012.06735.x
57. Bilsborrow JB, Doherty E, Tilstam PV, Bucala R. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus. Expert Opin Ther Targets 2019; 23(9):733-744. DOI: https://doi.org/10.1080/14728222.2019.1656718
58. Gu R, Santos LL, Ngo D, Fan H, Singh PP, Fingerle-Rowson G, Bucala R, Xu J, Quinn JM, Morand EF. Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis. Cytokine 2015; 72(2):135-145. DOI: https://doi.org/10.1016/j.cyto.2014.11.015
59. Stoppe C, Rex S, Goetzenich A, Kraemer S, Emontzpohl C, Soppert J, Averdunk L, Sun Y, Rossaint R, Lue H, Huang C, Song Y, Pantouris G, Lolis E, Leng L, Schulte W, Bucala R, Weber C, Bernhagen J. Interaction of MIF family proteins in myocardial ischemia/reperfusion damage and their influence on clinical outcome of cardiac surgery patients. Antioxid Redox Signal 2015; 23(11):865-879. DOI: https://doi.org/10.1089/ars.2014.6243
60. Kim EY, Moudgil KD. Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunol Lett 2008; 120(1-2):1-5. DOI: https://doi.org/10.1016/j.imlet.2008.07.008
61. Calandra T, Roger T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 2003; 3:791-800. https://doi.org/10.1038/nri1200
62. Noe JT, Mitchell RA. MIF-dependent control of tumor immunity. Front Immunol 2020; 11:609948. DOI: https://doi.org/10.3389/fimmu.2020.609948
63. Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, Une Y, Todo S. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 1998; 4(11):707-714.
64. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A, Nagasue N. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005; 103(3):588-598. DOI: https://doi.org/10.1002/cncr.20818
65. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer 2011; 2(4):466-474. DOI: https://doi.org/10.1177/1947601911408889
66. Zhang Y, Zhu W, He H, Fan B, Deng R, Hong Y, Liang X, Zhao H, Li X, Zhang F. Macrophage migration inhibitory factor rejuvenates aged human mesenchymal stem cells and improves myocardial repair. Aging (Albany NY) 2019; 11(24):12641-12660. DOI: https://doi.org/10.18632/aging.102592
67. Xia W, Zhang F, Xie C, Jiang M, Hou M. Macrophage migration inhibitory factor confers resistance to senescence through CD74-dependent AMPK-FOXO3a signaling in mesenchymal stem cells. Stem Cell Res Ther 2015; 6(1):82. DOI: https://doi.org/10.1186/s13287-015-0076-3
68. Kindt N, Journe F, Laurent G, Saussez S. Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets. Oncol Lett 2016; 12(4):2247-2253. DOI: https://doi.org/10.3892/ol.2016.4929
69. Liu W, Liu SY, He YB, Huang RL, Deng SY, Ni GX, Yu B. MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor. Biomed Pharmacother 2017; 87:621-627. DOI: https://doi.org/10.1016/j.biopha.2016.12.121
70. Wang WM, Liu JC. Effect and molecular mechanism of mir-146a on proliferation of lung cancer cells by targeting and regulating MIF gene. Asian Pac J Trop Med 2016; 9(8):806-811. DOI: https://doi.org/10.1016/j.apjtm.2016.06.001
71. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag 2006; 2(3):213-219. DOI: https://doi.org/10.2147/vhrm.2006.2.3.213
72. Marshall JD, Sauler M, Tonelli A, Rao Y, Bucala R, Lee PJ, Fares WH. Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension. Pulm Circ 2017; 7(3):730-733. DOI: https://doi.org/10.1177/2045893217724141
73. Munaut C, Boniver J, Foidart JM, Deprez M. Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression. Neuropathol Appl Neurobiol 2002; 28(6):452-460. DOI: https://doi.org/10.1046/j.1365-2990.2002.00416.x
74. Jia L, Chen J, Xie C, Shao L, Xu Z, Zhang L. microRNA-1228⁎ impairs the pro-angiogenic activity of gastric cancer cells by targeting macrophage migration inhibitory factor. Life Sci 2017; 180:9-16. DOI: https://doi.org/10.1016/j.lfs.2017.04.023
75. Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer: Macrophage migration inhibitory factor (MIF)--the potential missing link. QJM 2010; 103(11):831-836. DOI: https://doi.org/10.1093/qjmed/hcq148
76. Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. J Hematol Oncol 2019; 12(1):76. DOI: https://doi.org/10.1186/s13045-019-0760-3
77. Simpson KD, Templeton DJ, Cross JV. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol 2012 Dec; 189(12):5533-5540. DOI: https://doi.org/10.4049/jimmunol.1201161
78. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015; 15(2):73-86. DOI: https://doi.org/10.1038/nri3789
79. Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 2015; 66:97-110. DOI: https://doi.org/10.1146/annurev-med-051013-052304
80. Hahne M, Schumann P, Mursell M, Strehl C, Hoff P, Buttgereit F, Gaber T. Unraveling the role of hypoxia-inducible factor (HIF)-1α and HIF-2α in the adaption process of human microvascular endothelial cells (HMEC-1) to hypoxia: Redundant HIF-dependent regulation of macrophage migration inhibitory factor. Microvasc Res 2018; 116:34-44. DOI: https://doi.org/10.1016/j.mvr.2017.09.004
81. Stewart DA, Yang Y, Makowski L, Troester MA. Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages. Mol Cancer Res 2012; 10(6):727-738. DOI: https://doi.org/10.1158/1541-7786.MCR-11-0604
82. Soumoy L, Kindt N, Ghanem G, Saussez S, Journe F. Role of macrophage migration inhibitory factor (MIF) in melanoma. Cancers (Basel) 2019; 11(4):529. DOI: https://doi.org/10.3390/cancers11040529
83. Hu CT, Guo LL, Feng N, Zhang L, Zhou N, Ma LL, Shen L, Tong GH, Yan QW, Zhu SJ, Bian XW, Lai MD, Deng YJ, Ding YQ. MIF, secreted by human hepatic sinusoidal endothelial cells, promotes chemotaxis and outgrowth of colorectal cancer in liver prometastasis. Oncotarget 2015; 6(26):22410-22423. DOI: https://doi.org/10.18632/oncotarget.4198
84. Zepeda-Nuño JS, Gutiérrez-Cortés E, Hernández-Bello J, Ángeles-Sánchez J, De la Cruz-Mosso U, Cruz Á, Muñoz-Valle JF. Macrophage migration inhibitory factor: A promising oncogenic serological biomarker for oral squamous cell carcinoma. Int J Immunopathol Pharmacol 2021; 35:20587384211038417. DOI: https://doi.org/10.1177/20587384211038417
85. Kok T, Wasiel AA, Cool RH, Melgert BN, Poelarends GJ, Dekker FJ. Small-molecule inhibitors of macrophage migration inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders. Drug Discov Today 2018; 23(11):1910-1918. DOI: https://doi.org/10.1016/j.drudis.2018.06.017
86. Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ, Tracey KJ. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005; 280(44):36541-36544. DOI: https://doi.org/10.1074/jbc.C500243200
87. Ioannou K, Cheng KF, Crichlow GV, Birmpilis AI, Lolis EJ, Tsitsilonis OE, Al-Abed Y. ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models. Int J Oncol 2014; 45(4):1457-1468. DOI: https://doi.org/10.3892/ijo.2014.2551
88. Varinelli L, Caccia D, Volpi CC, Caccia C, De Bortoli M, Taverna E, Gualeni AV, Leoni V, Gloghini A, Manenti G, Bongarzone I. 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas. Endocr Relat Cancer 2015; 22(5):759-775. DOI: https://doi.org/10.1530/ERC-15-0299
89. Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, Bucala R, Cappello M, Gross M, Gaeta F, Johnson K, Lolis EJ. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 2010; 107(25):11313-11318. DOI: https://doi.org/10.1073/pnas.1002716107
90. Cavalli E, Ciurleo R, Petralia MC, Fagone P, Bella R, Mangano K, Nicoletti F, Bramanti P, Basile MS. Emerging role of the macrophage migration inhibitory factor family of cytokines in neuroblastoma. Pathogenic effectors and novel therapeutic targets? Molecules 2020; 25(5):1194. DOI: https://doi.org/10.3390/molecules25051194
91. Nagarajan P, Tober KL, Riggenbach JA, Kusewitt DF, Lehman AM, Sielecki T, Pruitt J, Satoskar AR, Oberyszyn TM. MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma. Mol Cancer Res 2014; 12(9):1292-1302. DOI: https://doi.org/10.1158/1541-7786.MCR-14-0255-T
92. Garai J, Lóránd T. Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: Current developments. Curr Med Chem 2009; 16(9):1091-1114. DOI: https://doi.org/10.2174/092986709787581842
93. Klemke L, De Oliveira T, Witt D, Winkler N, Bohnenberger H, Bucala R, Conradi LC, Schulz-Heddergott R. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis 2021; 12(2):155. DOI: https://doi.org/10.1038/s41419-021-03426-z
94. Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. Cell Death Dis 2014; 5(1):e980. DOI: https://doi.org/10.1038/cddis.2013.508
95. Kim JH, Lee J, Bae SJ, Kim Y, Park BJ, Choi JW, Kwon J, Cha GH, Yoo HJ, Jo EK, Bae YS, Lee YH, Yuk JM. NADPH oxidase 4 is required for the generation of macrophage migration inhibitory factor and host defense against Toxoplasma gondii infection. Sci Rep 2017; 7(1):6361. DOI: https://doi.org/10.1038/s41598-017-06610-4
96. Kerschbaumer RJ, Rieger M, Völkel D, Le Roy D, Roger T, Garbaraviciene J, Boehncke WH, Müllberg J, Hoet RM, Wood CR, Antoine G, Thiele M, Savidis-Dacho H, Dockal M, Ehrlich H, Calandra T, Scheiflinger F. Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF. J Biol Chem 2012; 287(10):7446-7455. DOI: https://doi.org/10.1074/jbc.M111.329664
97. Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Volkel D, Youssef A, de Jong FA, Tsimberidou AM. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol 2020; 86(9):1836-1848. DOI: https://doi.org/10.1111/bcp.14289
98. He XX, Chen K, Yang J, Li XY, Gan HY, Liu CY, Coleman TR, Al-Abed Y. Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 2009; 15(1-2):1-10. DOI: https://doi.org/10.2119/molmed.2008.00107
99. Zeng J, Quan J, Xia X. Transient transfection of macrophage migration inhibitory factor small interfering RNA disrupts the biological behavior of oral squamous carcinoma cells. Mol Med Rep 2016; 13(1):174-180. DOI: https://doi.org/10.3892/mmr.2015.4525. Erratum in: Mol Med Rep 2016; 14(1):614.
100. Dean AQ, Luo S, Twomey JD, Zhang B. Targeting cancer with antibody-drug conjugates: Promises and challenges. MAbs 2021; 13(1):1951427. DOI: https://doi.org/10.1080/19420862.2021.1951427. Erratum in: MAbs 2021; 13(1):1966993.
101. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol Oncol 2012; 6(2):155-176. DOI: https://doi.org/10.1016/j.molonc.2012.02.004
2. Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858. Nutr Rev 1989; 47(1):23-25. DOI: https://doi.org/10.1111/j.1753-4887.1989.tb02747.x
3. Francescone R, Hou V, Grivennikov SI. Microbiome, inflammation, and cancer. Cancer J 2014; 20(3):181-189. DOI: https://doi.org/10.1097/PPO.0000000000000048
4. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2017; 9(6):7204-7218. DOI: https://doi.org/10.18632/oncotarget.23208
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140(6):883-899. DOI: https://doi.org/10.1016/j.cell.2010.01.025
6. Fan Y, Mao R, Yang J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 2013; 4(3):176-185. DOI: https://doi.org/10.1007/s13238-013-2084-3
7. Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res 2014; 2(9):823-830. DOI: https://doi.org/10.1158/2326-6066.CIR-14-0112
8. Kasama T, Ohtsuka K, Sato M, Takahashi R, Wakabayashi K, Kobayashi K. Macrophage migration inhibitory factor: A multifunctional cytokine in rheumatic diseases. Arthritis 2010; 2010:106202. DOI: https://doi.org/10.1155/2010/106202
9. Sugimoto H, Taniguchi M, Nakagawa A, Tanaka I, Suzuki M, Nishihira J. Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 A resolution. Biochemistry 1999; 38(11):3268-3279. DOI: https://doi.org/10.1021/bi982184o
10. Grieb G, Merk M, Bernhagen J, Bucala R. Macrophage migration inhibitory factor (MIF): A promising biomarker. Drug News Perspect 2010; 23(4):257-264. DOI: https://doi.org/10.1358/dnp.2010.23.4.1453629
11. Schinagl A, Thiele M, Douillard P, Völkel D, Kenner L, Kazemi Z, Freissmuth M, Scheiflinger F, Kerschbaumer RJ. Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer. Oncotarget 2016; 7(45):73486-73496. DOI: https://doi.org/10.18632/oncotarget.11970
12. Guda MR, Rashid MA, Asuthkar S, Jalasutram A, Caniglia JL, Tsung AJ, Velpula KK. Pleiotropic role of macrophage migration inhibitory factor in cancer. Am J Cancer Res 2019; 9(12):2760-2773
13. Bloom J, Metz C, Nalawade S, Casabar J, Cheng KF, He M, Sherry B, Coleman T, Forsthuber T, Al-Abed Y. Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. J Biol Chem 2016; 291(51):26502-26514. DOI: https://doi.org/10.1074/jbc.M116.743328
14. Skeens E, Pantouris G, Shah D, Manjula R, Ombrello MJ, Maluf NK, Bhandari V, Lisi GP, Lolis EJ. A cysteine variant at an allosteric site alters MIF dynamics and biological function in homo- and heterotrimeric assemblies. Front Mol Biosci 2022; 9:783669. DOI: https://doi.org/10.3389/fmolb.2022.783669
15. Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol 2005; 18(1):41-78. DOI: https://doi.org/10.1089/vim.2005.18.41
16. Trivedi-Parmar V, Jorgensen WL. Advances and insights for small molecule inhibition of macrophage migration inhibitory factor. J Med Chem 2018; 61(18):8104-8119. DOI: https://doi.org/10.1021/acs.jmedchem.8b00589
17. Stamps SL, Fitzgerald MC, Whitman CP. Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor. Biochemistry 1998; 37(28):10195-10202. DOI: https://doi.org/10.1021/bi9806955
18. Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, Jüttner S, Brunner H, Bernhagen J. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 1998; 280(1):85-102. DOI: https://doi.org/10.1006/jmbi.1998.1864
19. Nguyen MT, Lue H, Kleemann R, Thiele M, Tolle G, Finkelmeier D, Wagner E, Braun A, Bernhagen J. The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis. J Immunol 2003; 170(6):3337-3347. DOI: https://doi.org/10.4049/jimmunol.170.6.3337
20. Fingerle-Rowson G, Koch P, Bikoff R, Lin X, Metz CN, Dhabhar FS, Meinhardt A, Bucala R. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 2003; 162(1):47-56. DOI: https://doi.org/10.1016/S0002-9440(10)63797-2
21. Calandra T, Roger T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 2003; 3(10):791-800. DOI: https://doi.org/10.1038/nri1200
22. Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R. Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1995; 1(7):781-8
23. Martinez-Guzman MA, Alvarado-Navarro A, Delgado-Rizo V, Garcia-Orozco A, Mayorga-Rodríguez JA, Pereira-Suarez AL, Fafutis-Morris M. Serum levels of migration inhibitory factor (MIF) and in situ expression of MIF and its receptor CD74 in lepromatous leprosy patients: A preliminary report. Front Immunol 2018; 9:246. DOI: https://doi.org/10.3389/fimmu.2018.00246
24. Merk M, Baugh J, Zierow S, Leng L, Pal U, Lee SJ, Ebert AD, Mizue Y, Trent JO, Mitchell R, Nickel W, Kavathas PB, Bernhagen J, Bucala R. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol 2009; 182(11):6896-6906. DOI: https://doi.org/10.4049/jimmunol.0803710
25. Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett 2003; 551(1-3):78-86. DOI: https://doi.org/10.1016/s0014-5793(03)00900-1
26. Lee YR, Joo HK, Lee EO, Cho HS, Choi S, Kim CS, Jeon BH. ATP binding cassette transporter A1 is involved in extracellular secretion of acetylated APE1/Ref-1. Int J Mol Sci 2019; 20(13):3178. DOI: https://doi.org/10.3390/ijms20133178
27. Burger-Kentischer A, Finkelmeier D, Thiele M, Schmucker J, Geiger G, Tovar GE, Bernhagen J. Binding of JAB1/CSN5 to MIF is mediated by the MPN domain but is independent of the JAMM motif. FEBS Lett 2005; 579(7):1693-1701. DOI: https://doi.org/10.1016/j.febslet.2005.01.080
28. Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, Bernhagen J. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 2006; 18(5):688-703. DOI: https://doi.org/10.1016/j.cellsig.2005.06.013
29. Lee JP, Foote A, Fan H, Peral de Castro C, Lang T, Jones SA, Gavrilescu N, Mills KH, Leech M, Morand EF, Harris J. Loss of autophagy enhances MIF/macrophage migration inhibitory factor release by macrophages. Autophagy 2016; 12(6):907-916. DOI: https://doi.org/10.1080/15548627.2016.1164358
30. Wu J, Deng X, Gao J, Gao W, Xiao H, Wang X, Zhang Y. Autophagy mediates the secretion of macrophage migration inhibitory factor from cardiomyocytes upon serum-starvation. Sci China Life Sci 2019; 62(8):1038-1046. DOI: https://doi.org/10.1007/s11427-019-9567-1
31. Rajasekaran D, Gröning S, Schmitz C, Zierow S, Drucker N, Bakou M, Kohl K, Mertens A, Lue H, Weber C, Xiao A, Luker G, Kapurniotu A, Lolis E, Bernhagen J. Macrophage migration inhibitory factor-CXCR4 receptor interactions: Evidence for partial allosteric agonism in comparison with CXCL12 chemokine. J Biol Chem 2016; 291(30):15881-15895. DOI: https://doi.org/10.1074/jbc.M116.717751
32. Schwartz V, Lue H, Kraemer S, Korbiel J, Krohn R, Ohl K, Bucala R, Weber C, Bernhagen J. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett 2009; 583(17):2749-2757. DOI: https://doi.org/10.1016/j.febslet.2009.07.058
33. Alampour-Rajabi S, El Bounkari O, Rot A, Müller-Newen G, Bachelerie F, Gawaz M, Weber C, Schober A, Bernhagen J. MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis. FASEB J 2015; 29(11):4497-511. DOI: https://doi.org/10.1096/fj.15-273904
34. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197(11):1467-1476. DOI: https://doi.org/10.1084/jem.20030286
35. Subbannayya T, Variar P, Advani J, Nair B, Shankar S, Gowda H, Saussez S, Chatterjee A, Prasad TS. An integrated signal transduction network of macrophage migration inhibitory factor. J Cell Commun Signal 2016; 10(2):165-170. DOI: https://doi.org/10.1007/s12079-016-0326-x
36. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008; 283(5):2784-2792. DOI: https://doi.org/10.1074/jbc.M703265200
37. Fex Svenningsen Å, Löring S, Sørensen AL, Huynh HUB, Hjæresen S, Martin N, Moeller JB, Elkjær ML, Holmskov U, Illes Z, Andersson M, Nielsen SB, Benedikz E. Macrophage migration inhibitory factor (MIF) modulates trophic signaling through interaction with serine protease HTRA1. Cell Mol Life Sci 2017; 74(24):4561-4572. DOI: https://doi.org/10.1007/s00018-017-2592-z
38. Kim MJ, Kim WS, Kim DO, Byun JE, Huy H, Lee SY, Song HY, Park YJ, Kim TD, Yoon SR, Choi EJ, Ha H, Jung H, Choi I. Macrophage migration inhibitory factor interacts with thioredoxin-interacting protein and induces NF-κB activity. Cell Signal 2017; 34:110-120. DOI: https://doi.org/10.1016/j.cellsig.2017.03.007
39. Shen L, Hu J, Lu H, Wu M, Qin W, Wan D, Li YY, Gu J. The apoptosis-associated protein BNIPL interacts with two cell proliferation-related proteins, MIF and GFER. FEBS Lett 2003; 540(1-3):86-90. DOI: https://doi.org/10.1016/s0014-5793(03)00229-1
40. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000; 408(6809):211-216. DOI: https://doi.org/10.1038/35041591
41. Gandhi J, Khera L, Gaur N, Paul C, Kaul R. Role of modulator of inflammation cyclooxygenase-2 in gamma herpesvirus mediated tumorigenesis. Front Microbiol 2017; 8:538. DOI: https://doi.org/10.3389/fmicb.2017.00538
42. Wang F, Wu H, Xu S, Guo X, Yang J, Shen X. Macrophage migration inhibitory factor activates cyclooxygenase 2-prostaglandin E2 in cultured spinal microglia. Neurosci Res 2011; 71(3):210-218. DOI: https://doi.org/10.1016/j.neures.2011.07.1821
43. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010; 2010:215158. DOI: https://doi.org/10.1155/2010/215158
44. Ramon S, Woeller CF, Phipps RP. The influence of Cox-2 and bioactive lipids on hematological cancers. Curr Angiogenes 2013; 2(2):135-142. DOI: https://doi.org/10.2174/2211552802999140131105947
45. Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V, Lara-Riegos J, Ramírez-Camacho MA, Alvarez-Sánchez ME. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol 2019; 9:1370. DOI: https://doi.org/10.3389/fonc.2019.01370
46. Yu X, Lin SG, Huang XR, Bacher M, Leng L, Bucala R, Lan HY. Macrophage migration inhibitory factor induces MMP-9 expression in macrophages via the MEK-ERK MAP kinase pathway. J Interferon Cytokine Res 2007; 27(2):103-109. DOI: https://doi.org/10.1089/jir.2006.0054
47. Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 1999; 19(8):5800-5810. DOI: https://doi.org/10.1128/MCB.19.8.5800
48. Dai Y, Jin S, Li X, Wang D. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget 2017; 8(1):1354-1368. DOI: https://doi.org/10.18632/oncotarget.13817. Erratum in: Oncotarget 2020; 11(4):488-489.
49. Mangano K, Mazzon E, Basile MS, Di Marco R, Bramanti P, Mammana S, Petralia MC, Fagone P, Nicoletti F. Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. Oncotarget 2018; 9(25):17951-17970. DOI: https://doi.org/10.18632/oncotarget.24885
50. Guo X, Xu S, Gao X, Wang J, Xue H, Chen Z, Zhang J, Guo X, Qian M, Qiu W, Li G. Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via CXCR4/AKT/EMT pathway in human glioblastoma cells. Oncotarget 2017; 8(46):80358-80372. DOI: https://doi.org/10.18632/oncotarget.18673
51. Amin MA, Haas CS, Zhu K, Mansfield PJ, Kim MJ, Lackowski NP, Koch AE. Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood 2006; 107(6):2252-2261. DOI: https://doi.org/10.1182/blood-2005-05-2011
52. Jung H, Seong HA, Ha H. Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J Biol Chem 2008; 283(29):20383-20396. DOI: https://doi.org/10.1074/jbc.M800050200
53. David JR, Remold HG, Higgins TJ, Liu DY, Churchill WH, Wilkinson PC, & Blussé van Oud Alblas A. MIF/MAF-macrophage interactions: Biochemical characterization of a putative glycolipid receptor for MIF and the existence and properties of two distinct MIFs. In: van Furth, R. (eds) Mononuclear Phagocytes. Springer, Dordrecht. 1980. DOI: https://doi.org/10.1007/978-94-009-8793-7_20
54. Wang F, Gao F, Jing L. Is macrophage migration inhibitory factor (MIF) the "control point" of vascular hypo-responsiveness in septic shock? Med Hypotheses 2005; 65(6):1082-1087. DOI: https://doi.org/10.1016/j.mehy.2005.05.047
55. Lan HY, Yang N, Metz C, Mu W, Song Q, Nikolic-Paterson DJ, Bacher M, Bucala R, Atkins RC. TNF-alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol Med 1997; 3(2):136-44.
56. Nishihira J. Molecular function of macrophage migration inhibitory factor and a novel therapy for inflammatory bowel disease. Ann N Y Acad Sci 2012; 1271(1):53-57. DOI: https://doi.org/10.1111/j.1749-6632.2012.06735.x
57. Bilsborrow JB, Doherty E, Tilstam PV, Bucala R. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus. Expert Opin Ther Targets 2019; 23(9):733-744. DOI: https://doi.org/10.1080/14728222.2019.1656718
58. Gu R, Santos LL, Ngo D, Fan H, Singh PP, Fingerle-Rowson G, Bucala R, Xu J, Quinn JM, Morand EF. Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis. Cytokine 2015; 72(2):135-145. DOI: https://doi.org/10.1016/j.cyto.2014.11.015
59. Stoppe C, Rex S, Goetzenich A, Kraemer S, Emontzpohl C, Soppert J, Averdunk L, Sun Y, Rossaint R, Lue H, Huang C, Song Y, Pantouris G, Lolis E, Leng L, Schulte W, Bucala R, Weber C, Bernhagen J. Interaction of MIF family proteins in myocardial ischemia/reperfusion damage and their influence on clinical outcome of cardiac surgery patients. Antioxid Redox Signal 2015; 23(11):865-879. DOI: https://doi.org/10.1089/ars.2014.6243
60. Kim EY, Moudgil KD. Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunol Lett 2008; 120(1-2):1-5. DOI: https://doi.org/10.1016/j.imlet.2008.07.008
61. Calandra T, Roger T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 2003; 3:791-800. https://doi.org/10.1038/nri1200
62. Noe JT, Mitchell RA. MIF-dependent control of tumor immunity. Front Immunol 2020; 11:609948. DOI: https://doi.org/10.3389/fimmu.2020.609948
63. Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, Une Y, Todo S. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 1998; 4(11):707-714.
64. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A, Nagasue N. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005; 103(3):588-598. DOI: https://doi.org/10.1002/cncr.20818
65. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer 2011; 2(4):466-474. DOI: https://doi.org/10.1177/1947601911408889
66. Zhang Y, Zhu W, He H, Fan B, Deng R, Hong Y, Liang X, Zhao H, Li X, Zhang F. Macrophage migration inhibitory factor rejuvenates aged human mesenchymal stem cells and improves myocardial repair. Aging (Albany NY) 2019; 11(24):12641-12660. DOI: https://doi.org/10.18632/aging.102592
67. Xia W, Zhang F, Xie C, Jiang M, Hou M. Macrophage migration inhibitory factor confers resistance to senescence through CD74-dependent AMPK-FOXO3a signaling in mesenchymal stem cells. Stem Cell Res Ther 2015; 6(1):82. DOI: https://doi.org/10.1186/s13287-015-0076-3
68. Kindt N, Journe F, Laurent G, Saussez S. Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets. Oncol Lett 2016; 12(4):2247-2253. DOI: https://doi.org/10.3892/ol.2016.4929
69. Liu W, Liu SY, He YB, Huang RL, Deng SY, Ni GX, Yu B. MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor. Biomed Pharmacother 2017; 87:621-627. DOI: https://doi.org/10.1016/j.biopha.2016.12.121
70. Wang WM, Liu JC. Effect and molecular mechanism of mir-146a on proliferation of lung cancer cells by targeting and regulating MIF gene. Asian Pac J Trop Med 2016; 9(8):806-811. DOI: https://doi.org/10.1016/j.apjtm.2016.06.001
71. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag 2006; 2(3):213-219. DOI: https://doi.org/10.2147/vhrm.2006.2.3.213
72. Marshall JD, Sauler M, Tonelli A, Rao Y, Bucala R, Lee PJ, Fares WH. Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension. Pulm Circ 2017; 7(3):730-733. DOI: https://doi.org/10.1177/2045893217724141
73. Munaut C, Boniver J, Foidart JM, Deprez M. Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression. Neuropathol Appl Neurobiol 2002; 28(6):452-460. DOI: https://doi.org/10.1046/j.1365-2990.2002.00416.x
74. Jia L, Chen J, Xie C, Shao L, Xu Z, Zhang L. microRNA-1228⁎ impairs the pro-angiogenic activity of gastric cancer cells by targeting macrophage migration inhibitory factor. Life Sci 2017; 180:9-16. DOI: https://doi.org/10.1016/j.lfs.2017.04.023
75. Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer: Macrophage migration inhibitory factor (MIF)--the potential missing link. QJM 2010; 103(11):831-836. DOI: https://doi.org/10.1093/qjmed/hcq148
76. Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. J Hematol Oncol 2019; 12(1):76. DOI: https://doi.org/10.1186/s13045-019-0760-3
77. Simpson KD, Templeton DJ, Cross JV. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol 2012 Dec; 189(12):5533-5540. DOI: https://doi.org/10.4049/jimmunol.1201161
78. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015; 15(2):73-86. DOI: https://doi.org/10.1038/nri3789
79. Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 2015; 66:97-110. DOI: https://doi.org/10.1146/annurev-med-051013-052304
80. Hahne M, Schumann P, Mursell M, Strehl C, Hoff P, Buttgereit F, Gaber T. Unraveling the role of hypoxia-inducible factor (HIF)-1α and HIF-2α in the adaption process of human microvascular endothelial cells (HMEC-1) to hypoxia: Redundant HIF-dependent regulation of macrophage migration inhibitory factor. Microvasc Res 2018; 116:34-44. DOI: https://doi.org/10.1016/j.mvr.2017.09.004
81. Stewart DA, Yang Y, Makowski L, Troester MA. Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages. Mol Cancer Res 2012; 10(6):727-738. DOI: https://doi.org/10.1158/1541-7786.MCR-11-0604
82. Soumoy L, Kindt N, Ghanem G, Saussez S, Journe F. Role of macrophage migration inhibitory factor (MIF) in melanoma. Cancers (Basel) 2019; 11(4):529. DOI: https://doi.org/10.3390/cancers11040529
83. Hu CT, Guo LL, Feng N, Zhang L, Zhou N, Ma LL, Shen L, Tong GH, Yan QW, Zhu SJ, Bian XW, Lai MD, Deng YJ, Ding YQ. MIF, secreted by human hepatic sinusoidal endothelial cells, promotes chemotaxis and outgrowth of colorectal cancer in liver prometastasis. Oncotarget 2015; 6(26):22410-22423. DOI: https://doi.org/10.18632/oncotarget.4198
84. Zepeda-Nuño JS, Gutiérrez-Cortés E, Hernández-Bello J, Ángeles-Sánchez J, De la Cruz-Mosso U, Cruz Á, Muñoz-Valle JF. Macrophage migration inhibitory factor: A promising oncogenic serological biomarker for oral squamous cell carcinoma. Int J Immunopathol Pharmacol 2021; 35:20587384211038417. DOI: https://doi.org/10.1177/20587384211038417
85. Kok T, Wasiel AA, Cool RH, Melgert BN, Poelarends GJ, Dekker FJ. Small-molecule inhibitors of macrophage migration inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders. Drug Discov Today 2018; 23(11):1910-1918. DOI: https://doi.org/10.1016/j.drudis.2018.06.017
86. Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ, Tracey KJ. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005; 280(44):36541-36544. DOI: https://doi.org/10.1074/jbc.C500243200
87. Ioannou K, Cheng KF, Crichlow GV, Birmpilis AI, Lolis EJ, Tsitsilonis OE, Al-Abed Y. ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models. Int J Oncol 2014; 45(4):1457-1468. DOI: https://doi.org/10.3892/ijo.2014.2551
88. Varinelli L, Caccia D, Volpi CC, Caccia C, De Bortoli M, Taverna E, Gualeni AV, Leoni V, Gloghini A, Manenti G, Bongarzone I. 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas. Endocr Relat Cancer 2015; 22(5):759-775. DOI: https://doi.org/10.1530/ERC-15-0299
89. Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, Bucala R, Cappello M, Gross M, Gaeta F, Johnson K, Lolis EJ. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 2010; 107(25):11313-11318. DOI: https://doi.org/10.1073/pnas.1002716107
90. Cavalli E, Ciurleo R, Petralia MC, Fagone P, Bella R, Mangano K, Nicoletti F, Bramanti P, Basile MS. Emerging role of the macrophage migration inhibitory factor family of cytokines in neuroblastoma. Pathogenic effectors and novel therapeutic targets? Molecules 2020; 25(5):1194. DOI: https://doi.org/10.3390/molecules25051194
91. Nagarajan P, Tober KL, Riggenbach JA, Kusewitt DF, Lehman AM, Sielecki T, Pruitt J, Satoskar AR, Oberyszyn TM. MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma. Mol Cancer Res 2014; 12(9):1292-1302. DOI: https://doi.org/10.1158/1541-7786.MCR-14-0255-T
92. Garai J, Lóránd T. Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: Current developments. Curr Med Chem 2009; 16(9):1091-1114. DOI: https://doi.org/10.2174/092986709787581842
93. Klemke L, De Oliveira T, Witt D, Winkler N, Bohnenberger H, Bucala R, Conradi LC, Schulz-Heddergott R. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis 2021; 12(2):155. DOI: https://doi.org/10.1038/s41419-021-03426-z
94. Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. Cell Death Dis 2014; 5(1):e980. DOI: https://doi.org/10.1038/cddis.2013.508
95. Kim JH, Lee J, Bae SJ, Kim Y, Park BJ, Choi JW, Kwon J, Cha GH, Yoo HJ, Jo EK, Bae YS, Lee YH, Yuk JM. NADPH oxidase 4 is required for the generation of macrophage migration inhibitory factor and host defense against Toxoplasma gondii infection. Sci Rep 2017; 7(1):6361. DOI: https://doi.org/10.1038/s41598-017-06610-4
96. Kerschbaumer RJ, Rieger M, Völkel D, Le Roy D, Roger T, Garbaraviciene J, Boehncke WH, Müllberg J, Hoet RM, Wood CR, Antoine G, Thiele M, Savidis-Dacho H, Dockal M, Ehrlich H, Calandra T, Scheiflinger F. Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF. J Biol Chem 2012; 287(10):7446-7455. DOI: https://doi.org/10.1074/jbc.M111.329664
97. Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Volkel D, Youssef A, de Jong FA, Tsimberidou AM. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol 2020; 86(9):1836-1848. DOI: https://doi.org/10.1111/bcp.14289
98. He XX, Chen K, Yang J, Li XY, Gan HY, Liu CY, Coleman TR, Al-Abed Y. Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 2009; 15(1-2):1-10. DOI: https://doi.org/10.2119/molmed.2008.00107
99. Zeng J, Quan J, Xia X. Transient transfection of macrophage migration inhibitory factor small interfering RNA disrupts the biological behavior of oral squamous carcinoma cells. Mol Med Rep 2016; 13(1):174-180. DOI: https://doi.org/10.3892/mmr.2015.4525. Erratum in: Mol Med Rep 2016; 14(1):614.
100. Dean AQ, Luo S, Twomey JD, Zhang B. Targeting cancer with antibody-drug conjugates: Promises and challenges. MAbs 2021; 13(1):1951427. DOI: https://doi.org/10.1080/19420862.2021.1951427. Erratum in: MAbs 2021; 13(1):1966993.
101. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol Oncol 2012; 6(2):155-176. DOI: https://doi.org/10.1016/j.molonc.2012.02.004
How to Cite
Stebbins, C. (2023). Is Macrophage Migration Inhibitory Factor a Link between Inflammation and Tumor?. Science Insights, 42(1), 777–786. https://doi.org/10.15354/si.23.re112
Issue
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.